UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

~~(Mark~~[X] QUARTERLY ~~One~~REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~[x]~~For the ~~QUARTERLY~~quarterly ~~REPORT~~period ~~PURSUANT~~ended TOFebruary ~~SECTION~~28, ~~13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~2022

~~For~~PURTHANOL RESOURCES ~~the quarterly period ended August 31, 2013~~LTD.

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to _______________

Commission File Number 000-33271

GLOBAL BIOTECH CORP

(Exact name of registrant as specified in its charter)

DELAWARE (State of Incorporation)		98-0229951 (I.R.S. Employer Identification No.)
2711 Centreville Rd Suite 400 Wilmington, Delaware		19808
(Address of principal executive offices)		(Zip Code)

Delaware 98-022951

(~~302~~State or other jurisdiction of incorporation or organization) ~~288-0658~~(I.R.S. Employer Identification No.)

2711 Centreville Rd Suite 400 Wilmington, Delaware 19808

(Address of principal executive offices) (Zip Code)

866-351-4141

(Registrant’s telephone number, including area code)

~~Indicate by check mark whether the registrant~~Securities ~~(1) has~~registered ~~filed~~pursuant ~~all reports required~~ to ~~be filed by~~ Section 13 ~~or 15~~12(db) of the ~~Securities Exchange~~ Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [x] No [ ]:

~~Indicate~~Title byof ~~check~~each ~~mark~~class ~~whether~~Trading ~~the~~Symbol(s) ~~registrant~~Name ~~is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions~~ of ~~“large~~each ~~accelerated filer,”~~exchange ~~“accelerated~~on ~~filer”~~which ~~and~~registered ~~“smaller~~Common ~~reporting~~PURT ~~company” in Rule 12b-2 of the Exchange Act. (Check one):~~N/A

~~Large~~Indicate by ~~Accelerated~~check ~~filer~~mark [whether ]the ~~Accelerated~~registrant ~~Filer~~(1) [has ]filed ~~Non-Accelerated~~all reports required to be filed by Section 13 or 15(d) of the Securities Exchange ~~Filer~~Act [of ]1934 ~~Smaller~~during ~~Reporting~~the ~~Company~~preceding ~~[x]~~12 months (or for such shorter period that the registrant was required to

~~Indicate~~file such byreports), ~~check~~and ~~mark~~(2) ~~whether~~has ~~the~~been ~~registrant~~subject isto asuch ~~shell company~~filing ~~(as~~requirements ~~determined~~for inthe ~~Rule~~past ~~12b-2~~90 ofdays. ( ~~the~~) ~~Exchange~~Yes ~~Act~~(X). ~~NO [x]~~ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). (_) yes (X) No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer (_) Accelerated filer (_) Non-accelerated filer (X) (Do not check if a smaller reporting company) Smaller reporting company (X) Emerging growth company (_)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. (_)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). (X)Yes ( ) No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court~~. Yes [ ] No [ ]~~

(_) Yes (_) No

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of ~~October~~November 14, ~~2013~~2022, ~~the~~there ~~aggregate~~were ~~market value~~244,038,890 shares of ~~the issuer's~~ common stock ~~based~~issued onand ~~its reported price on the OTC held by non-affiliates of the issuer was approximately $1,544,739~~outstanding.

As TABLE of ~~October 1, 2013, the Registrant had 154,473,890 shares of Common Stock outstanding.~~CONTENTS

INDEX PART I: FINANCIAL INFORMATION Item 1. Financial Statements Balance Sheets at August 31, 2013 (Unaudited) and November 30, 2012 Statements of Operations (Unaudited) for the Nine and Three months ended August 31, 2013 and August 31, 2012 and from Inception (November 2, 1998) to August 31, 2013. Statement of Cash Flows (Unaudited) for the Nine months ended August 31, 2013 and August 31, 2012 and from Inception (November 2, 1998) to August 31, 2013. Notes to the Financial Statements (Unaudited). Item 2. Plan of Operations Item 4T. Controls and Procedures PART II: OTHER INFORMATION Item b. Exhibits and Reports On Form SIGNATURES

PART I—FINANCIAL INFORMATION	3
Item 1. Condensed Consolidated Financial Statements.	3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.	9
Item 3. Quantitative and Qualitative Disclosures About Market Risk.	9
Item 4. Controls and Procedures.	9
PART II—OTHER INFORMATION	10
EXHIBIT INDEX	10
SIGNATURES	12
Exhibit 31.1	13
Exhibit 32.1	14

GLOBAL BIOTECH CORP.
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEETS
	August 31, 2013			November 30, 2012
		(Unaudited)
ASSETS
Current Assets
Cash	$	23,535		$	7
Prepaid expenses		58,175			95,581
Short term investments		195,046			198160
Total current assets		276,756			293,748
Property & Equipment (Net)		86,430			86,430
Total Assets	$	363,186		$	380,178
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Bank overdraft	$	—		$	—
Accounts payables and accrued liabilities		976,435			972,551
Notes Payable related party		45,244			46,352
Notes Payable		1,458,259			1,248,156
Total current liabilities		2,479,938			2,267,059
Stockholders' Equity
Preferred stock, $0.0001 par value authorized 80,000,000 shares 0 shares issued and outstanding August 31, 2013 and November 30, 2012		—			—
Common stock, $0.0001 par value authorized 260,000,000 shares: issued and outstanding 82,073,890 August 31, 2013 and 82,073,890 November 30,2012		8,207			8,207
Paid in capital		1,667,790			1,667,790
Deficit accumulated during the development stage		(3,792,749	)		(3,562,878	)
Total Stockholders' (Deficit) Equity		(2,116,752	)		(1,886,881	)
Total liabilities and Stockholders' Equity	$	363,186		$	380,178
See the accompanying notes to financial statements.

PART I—FINANCIAL INFORMATION

GLOBAL BIOTECH CORP.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF OPERATIONS
(UNAUDITED)
	Three Months Ended August 31,2013			Three Months Ended August 31,2012			Nine Months Ended August 31,2013			Nine Months Ended August 31,2012			Inception to August 31,2013
Revenues:	$	—		$	—		$	—		$	—		$	944,811
Cost of Revenues:		—			—			—			—			603,063
		—			—			—			—			341,748
Operating Expenses:
Bad Debt Exp		—			—			—			—			120,844
Licensing rights		—			—			—			—			700,000
Depreciation Exp		—			—			—			—			73,274
Marketing		30,273			—			30,273			—			266,539
Professional Fees		2,000			2,000			6,000			6,000			231,295
Selling, general and administrative		46,854			13,336			179,552			39,978			1,911,283
Total Operating Expenses		79,127			15,336			215,825			45,978			3,303,235
(Loss) before other income (expense)		(79,127	)		(15,336	)		(215,825	)		(45,978	)		(2,961,487	)
Other income (expense):
Other income		—			—			—			—			85,005
Foreign exchange gain (loss)		11,269			(15,878	)		30,531			(15,878	)		(18,665	)
Interest income		2,402			2,287			7,206			6,861			144,395
Interest Expense		(16,789	)		(17,249	)		(51,783	)		(51,011	)		(560,521	)
Gain on Sale of Investment		—			—			—			—			359,583
Impairment Loss		—			—			—			—			(849,831	)
Write down - leasehold improvements		—			—			—			—			(2,663	)
Write down - Notes receivable		—			—			—			—			11,435
Total other income (Expense)		(3,118	)		(30,840	)		(14,046	)		(60,028	)		(831,262	)
Net (Loss)	$	(82,245	)	$	(46,176	)	$	(229,871	)	$	(106,006	)	$	(3,792,749	)
Basic weighted avg. common shares outstanding		82,073,890			82,073,890			82,073,890			82,073,890
Basic and Diluted (Loss) per common share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
See the accompanying notes to financial statements.

Item 1. Condensed Consolidated Financial Statements.

GLOBAL BIOTECH CORP.
(A DEVELOPMENT STAGE COMPANY)
Statement of Cash Flows (Unaudited)
							From Inception
	Nine months ended						(November 2, 1998)
	August 31, 2013			August 31, 2012			to August 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$	(229,871	)	$	(106,006	)	$	(3,792,749	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense		—			—			73,274
Common stock issued for services		—			—			436,143
Gain on sale of Investment								(359,583	)
Impairment Loss		—			—			849,831
Write down of leasehold improvements		—			—			2,663
Write down of notes receivable		—			—			(11,435	)
Accrued interest expense - note payable		51,783			51,011			451,033
Accrued interest income - note receivable		(7,206	)		(6,861	)		(138,869	)
Changes in operating assets and liabilities
(Increase) Decrease - accounts receivable/prepaids		37,406			37,401			(58,175	)
(Increase) Decrease in notes receivable		10,320			(5,069	)		(455,868	)
Increase (decrease) - accounts payable		3,884			11,367			976,435
Net Cash Provided by (used in) Operating Activities		(133,684	)		(18,157	)		(2,027,300	)
Cash Flows from Investing Activities
Net sale (purchase of fixed assets		—			—			(60,937	)
Purcase of short term investments		—			—			(168,560	)
Proceeds from sale of investment shares		—			—			489,061
Net Cash Provided by (used in) Investing Activities		—			—			259,564
Cash Flows from Financing Activities
Bank Advances		—			2			—
Issue of Common stock		—			—			156,262
Payment of common stock subscription receivable		—			—			206,239
Proceeds from notes payable & related party		157,212			18,146			1,428,770
Net Cash provided by (used in) Financing Activities		157,212			18,148			1,791,271
Net Increase (Decrease) in Cash		23,528			(9	)		23,535
Cash at Beginning of Period		7			9			—
Cash at End of Period	$	23,535		$	—		$	23,535
Supplemental Cash Flow Disclosures:
Cash paid during period for interest
Cash paid during period for taxes
See accompanying notes to Financial Statements

PURTHANOL RESOURCES LIMITED

~~GLOBAL BIOTECH CORP.~~BALANCE SHEETS

(A DEVELOPMENT STAGE COMPANY)

	February 28, 2022			November 30, 2021
	(unaudited)
ASSETS

NON CURRENT ASSETS
Property, Plant, and Equipment, net	$	-		$		-

TOTAL ASSETS	$	-		$		-

LIABILITIES AND STOCKHOLDERS’ DEFICIT

CURRENT LIABILITIES
Accounts payable	$	40,662			$		39,249
Due to related party		850,484					837,984
TOTAL LIABILITIES		891,146					877,233

STOCKHOLDERS’ DEFICIT
Preferred stock, $0.0001 par value, 80,000,000 shares authorized
None issued and outstanding		-					-
Common stock, $0.0001 par value, 260,000,000 shares authorized,
244,038,890 shares issued and outstanding		24,403					24,403
Additional paid-in capital		3,242,350					3,242,350
Accumulated deficit		(4,157,899)					(4,143,986

TOTAL STOCKHOLDERS’ DEFICIT		(891,146)	)				(877,233

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	-			$		-

~~NOTES~~The accompanying TOnotes ~~THE~~are ~~INTERIM~~an ~~FINANCIAL~~integral ~~STATEMENTS~~part of these unaudited financial statements.

~~AUGUST 31, 2013~~3

~~(UNAUDITED)~~PURTHANOL RESOURCES LIMITED.

~~NOTE 1 – BASIS~~ STATEMENTS OF ~~PRESENTATION~~OPERATIONS

~~The accompanying unaudited financial statements~~For ~~of GLOBAL BIOTECH CORP. have been prepared in accordance with generally accepted accounting principles for interim financial information and with~~ the ~~instructions~~Three tomonths ~~Form~~ended ~~10-Q~~February ~~and Rule 10-01 of Regulation S-X. The financial statements reflect all adjustments consisting of normal recurring adjustments which~~28, in2022 ~~the opinion of management, are necessary for a fair presentation of the results for the periods shown. Accordingly, they do not include all of the information~~ and ~~footnotes required by generally accepted accounting principles for complete financial statements.~~2021

These financial statements should be read in conjunction with the audited financial statements and footnotes thereto included for the year ended November 30, 2012 for GLOBAL BIOTECH CORP. on form 10 K as filed with the Securities and Exchange Commission.(unaudited)

The preparation of financial statements in conformity with generally accepted accounting principles of United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and that effect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

	Three months ended, February 28, 2022			Three months ended, February 29, 2021
Brokerage fees	$	507		$	507
Administrative fees		12,500			12,500
Professional Fees		906			—
TOTAL OPERATING EXPENSES		(13,913	)		(13,007	)
NET LOSS	$	(13,913	)	$	(13,007	)
LOSS PER COMMON SHARE - BASIC AND DILUTED	$	(0.00	)	$	(0.00	)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING – BASIC AND DILUTED		244,038,890			244,038,890

~~NOTE~~The accompanying 2notes –are ~~SUMMARY~~an OFintegral ~~SIGNIFICANT~~part ~~ACCOUNTING~~of ~~POLICIES~~these unaudited financial statements.

~~Earnings (Loss) Per Share~~4

~~The Company computes net income (loss) per~~Purthanol ~~share~~Resources ~~in accordance with ASC 260, Earnings per Share~~Limited. ASC 260 specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. Basic earnings (loss) per Common share ("EPS") calculations are determined by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted earning per common share calculations are determined by dividing net income (loss) by the weighted average number of common shares and dilutive common share equivalents outstanding. During the periods presented common stock equivalents were not considered, as their effect would be anti-dilutive.

~~Recent~~STATEMENTS OF ~~Accounting~~CHANGES ~~Pronouncements~~IN STOCKHOLDERS’ DEFICIT

~~The Company has implemented all new accounting~~Three ~~pronouncements~~months ~~that~~Ended ~~are~~February in28, ~~effect~~2022 and that may impact its financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.2021

~~NOTE 3 – GOING CONCERN~~(unaudited)

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The company reported net losses of $82,245 and $229,871 for the three months and nine months ended August 31, 2013 as well as reporting net losses of $3,792,749 from inception (November 2, 1998) to August 31, 2013. At August 31, 2013 the Company had negative working capital of $2,203,182 and stockholders’ deficit of $2,116,752. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

	Common Stock				Paid-in			Additional Accumulated
	Number of shares		Amount		Capital			Deficit			Total
Balance, November 30, 2020		244,038,890		24,403		3,242,350			(4,086,958	)		(820,205	)

Net loss		-		-		-			(13,007	)		(13,007	)

Balance, February 28, 2021		244,038,890	$	24,403	$	3,242,350	)	$	(4.099,965	)	$	(833,212	)


Balance, November 30, 2021		244,038,890		24,403		3,242,350			(4,143,986	)		(877,233	)

Net loss		-		-		-			(13,913	)		(13,913	)

Balance, February 28, 2022		244,038,890	$	24,403	$	3,242,350		$	(4,157,899	)	$	(891,146	)

The ~~officers and directors are committed to~~ ~~help~~accompanying innotes raising funds to fill any operating cash flow shortages during the next fiscal year until the organization can generate sufficient funds from operations to meet current operating expenses and overhead, although there are noan ~~guarantees~~integral ~~that~~part ~~this~~of ~~commitment will~~these beunaudited ~~met~~financial statements.

~~GLOBAL BIOTECH CORP.~~5

(APURTHANOL RESOURCES ~~DEVELOPMENT STAGE COMPANY)~~LIMITED

~~NOTES~~ STATEMENTS OF TOCASH ~~THE INTERIM FINANCIAL STATEMENTS~~FLOWS

~~AUGUST~~For Three 31months ended February 28, ~~2013~~2022 and 2021

(~~UNAUDITED~~unaudited)

NOTE 4. SHORT TERM INVESTMENT

	Three months ended February 28, 2022			Three months ended February 28, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(13,913	)	$	(13,007	)
Adjustments to reconcile net loss to net cash used in operating activities:
Changes in operating assets and liabilities:
Accounts payable		1,413			507
NET CASH USED IN OPERATING ACTIVITIES		(12,500	)		(12,500	)
CASH FLOWS FROM FINANCING ACTIVITIES
Advances from related party		12,500			12,500
NET CASH PROVIDED BY FINANCING ACTIVITIES		12,500			12,500
NET CHANGE IN CASH		—			—
CASH, BEGINNING OF PERIOD		—			—
CASH, END OF PERIOD	$	—		$	—

~~As of August 31, 2013, the Company had purchased a term deposit~~The inaccompanying ~~the~~notes ~~amount~~are ofan ~~CAD172,000~~integral ~~(USD~~part ~~163,400), bearing interest rate~~ of ~~5%,~~these ~~maturing~~unaudited onfinancial ~~November 6, 2013~~statements. ~~As of August 31, 2013, the Company accrued 31,646 USD of interest income. No withdrawals allowed for first 90 days and 90 days early withdrawal notice needed. Early withdrawal interest rate - 1 ½%.~~

~~NOTE 5. PROPERTY & EQUIPMENT~~6

~~On August 15, 2007 the Company acquired Oxygenation~~PURTHANOL ~~Equipment~~RESOURCES ~~with a cost of $605,000 in exchange for common shares~~LIMITED.

	August 31,		November 30,
	2013		2012
Oxygenation equipment	$	605,000	$	605,000
Less: Impairment Loss		518,570		518,570
Net Property and Equipment	$	86,430	$	86,430

NOTES TO THE FINANCIAL STATEMENTS

~~NOTE~~February 28, ~~6. NOTE PAYABLE TO RELATED PARTY~~2022

~~Note payable to related party as of August 31, 2013 and November 30, 2012 consist of the following:~~(unaudited)

		August 31, 2013		November 30, 2012
Due to an officer, unsecured, non-interest bearing		$45,244		$46,352

NOTE 1 – NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

~~NOTE~~PURTHANOL RESOURCES 7LIMITED (formerly Global Biotech Corp.) ~~NOTES~~(the ~~PAYABLE~~Company) was incorporated in the State of Delaware on November 2, 1998, to be an Application Service provider in the E-health sector. On March 5, 2003, this business was sold, market, unsuccessfully. On February 25, 2005, it discontinued its vehicle tracking business. On August 15, 2007, the Company entered the oxygenated beverage market. The Company changed its mission and its objective was to produce Bio fuel alternatives, via the acquisition of the Purthanol process in September 2013 and the acquisition of Bio-Cardel Quebec in December 2013. The Company changed its name from

~~Note~~Global Biotech ~~payable~~Corp. asto ofPurthanol ~~August~~Resources 31Limited on September 30, 2013. Currently the Company has not been operating , and ~~November~~has not been operating, 30and has been inactive since 2015.There are no operations, ~~2012~~sales, ~~consist~~and ofactivities ~~the~~as ~~following:~~far as marketing and production.

	August 31, 2013		November 30, 2012
Note payable to: Millenia Hope Inc. unsecured, with annual interest rate 7%.	$	640,895	$	608,392
Third parties, unsecured with annual interest of 4%, commencing July 1, 2009		104,147		107,063
Convertible note payable to third parties with annual interest of 2%,commencing March 1, 2011 Loan is convertible to common shares of Global Biotech at par to the lowest daily trading price of the shares on the conversion request date		204,328		213,612
Third parties, unsecured ,non-interest bearing		190,000
Convertible note payable to third parties with annual interest of 8%,commencing April 30,2009 Loan is convertible to common shares of Global Biotech at the lesser of $1.00 per share or the average closing price of the shares for the 5 business days prior to conversion		318,889		319,089
	$	1,458,259	$	1,248,156

Basis of Presentation – Unaudited Financial Statements

~~There~~The accompanying ~~are~~unaudited nofinancial ~~beneficial~~statements ~~conversion~~have ~~features~~been prepared in accordance with generally accepted accounting principles for financial ~~because~~information and with the ~~Company~~instructions to Form 10-Q. They do not include all information and footnotes required by United States generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there has ~~conversion~~been ~~right~~no material changes in the information disclosed in the notes to the financial statements for the fiscal year ended November 30, 2021 included in the Company’s 10-K filed with the Securities and Exchange Commission. The unaudited financial statements should be read in conjunction with those financial statements included in the Form 10-K. In the opinion of Management, all adjustments considered necessary for a fair presentation, consisting solely of normal recurring adjustments, have been made. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending November 30, 2022.

~~GLOBAL~~Risks and ~~BIOTECH CORP.~~Uncertainties

(AThe pandemic ~~DEVELOPMENT~~caused ~~STAGE~~by ~~COMPANY~~an outbreak of a new strain of coronavirus (“COVID-19”) has resulted, and is likely to continue to result, in significant national and global economic disruption and may adversely affect our business. Based on the Company’s current assessment, the Company does not expect some material impact on its long-term operation due to the worldwide spread of the COVID-19 virus. However, the Company is actively monitoring this situation and the possible effects on its financial condition, operations, suppliers, industry, and workforce.

~~NOTES~~Use of TOEstimates ~~THE~~and ~~INTERIM FINANCIAL STATEMENTS~~Assumptions

~~AUGUST~~Preparation of 31the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Accordingly, ~~2013~~actual results could differ from those estimates.

~~(UNAUDITED)~~Cash and Cash Equivalents

~~NOTE~~For purposes 8.of ~~STOCKHOLDERS'~~the ~~EQUITY~~statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.

~~The stockholders' equity section of the Company~~Earnings ~~contains~~(Loss) ~~the~~per ~~following~~Common ~~classes of capital stock as of August 31, 2013 and November 30, 2012:~~Share

~~Common~~The basic ~~stock,~~earnings $(loss) ~~0.0001~~per ~~par~~common ~~value;~~share ~~260,000,000~~is ~~shares~~calculated ~~and~~by ~~260,000,000~~dividing the Company’s net income (loss) available to common shareholders by the weighted average number of common shares ~~authorized~~during the period. The diluted earnings (loss) per share is calculated by dividing the ~~August~~Company’s ~~31,~~net ~~2013~~income ~~and~~(loss) ~~November~~available ~~30,~~to ~~2012~~common :shareholders ~~82,073,890~~by the diluted weighted average number of shares ~~issued~~outstanding ~~and~~during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. Diluted earnings (loss) per share are the same as basic earnings (loss) per share due to the lack of ~~August~~dilutive items ~~31,~~in ~~2013~~the ~~and~~Company. ~~November~~As 30of February 28, ~~2012~~2022, there were no common stock equivalents outstanding.

~~Preferred Stock, $0.0001 par value; 80,000,000 shares authorized August 31, 2013 and November 30, 2012. Zero (0) shares issued and outstanding as of August 31, 2013 and November 30, 2012.~~7

~~NOTE 9 - SUBSEQUENT EVENTS~~Income Taxes

InThe Company ~~accordance~~follows ~~with~~the ~~ASC~~asset ~~855~~and liability method of accounting for income taxes. Under this method, ~~Subsequent~~deferred tax assets and liabilities ~~Events,~~are recognized for the ~~Company~~future ~~has~~tax ~~evaluated~~consequences ~~subsequent~~attributable ~~events~~to ~~through~~differences between the ~~date~~financial statement carrying mounts of ~~issuance~~existing assets and liabilities and their respective tax balances and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted or substantially enacted tax rates expected to apply to the taxable income in the years in which those differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the ~~unaudited~~period ~~interim~~that ~~financial~~includes ~~statements~~the date of enactment or substantive enactment.

~~As of September 10, 2013, Global acquired from Purthanol International~~Recent ~~all~~Accounting the intellectual property, process know-how and methodology, etc. for the production of Athanol, a green- technology ethanol fuel alternative, produced via the Purthanol Process. Further, the Company has acquired purchase orders of $28.5 million USD for the purchase of ethanol or Athanol from Purthanol International, delivery within the ensuing 12 months. Any other revenue generated via the Purthanol Process, will belong wholly and solely to Global as of the signing of this Agreement. The consideration for the above was 70 million (70,000,000) restricted common shares, valued at $0.01 per share or $700,000 USD.Standards

OnThe Company ~~September~~does ~~23,~~not ~~2013~~expect ~~Global~~the ~~issued 2.4~~adoption ~~million~~of ~~restricted~~any ~~common~~recent ~~shares,~~accounting ~~valued~~standards atto ~~$24,000,~~have ina ~~settlement~~material ofimpact ~~consulting~~on ~~services~~its ~~rendered~~financial statements.

~~ITEM 6 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL~~Subsequent ~~CONDITION AND RESULTS OF OPERATIONS.~~Events

~~Special~~The Company ~~Note~~has ~~Regarding~~evaluated ~~Forward-Looking~~subsequent ~~Statements~~events through the date the financial statements were issued for disclosure purposes. No events have occurred subsequent to balance sheet date and through date of this filing that would require adjustment to or disclosure in the financial statements.

~~Some of the statements under "Plan of Operations," "Business"~~NOTE ~~and~~2 ~~elsewhere~~– inGOING this registration statement are forward-looking statements that involve risks and uncertainties. These forward-looking statements include statements about our plans, objectives, expectations, intentions and assumptions and other statements contained herein that are not statements of historical fact. You can identify these statements by words such as "may," "will," "should," "estimates," "plans," "expects," "believes," "intends" and similar expressions. We cannot guarantee future results, levels of activity, performance or achievements. Our actual results and the timing of certain events may differ significantly from the results discussed in the forward-looking statements. You are cautioned not to place undue reliance on any forward-looking statements.CONCERN

~~Plan~~To date the Company has generated no revenues from its business operations and has incurred operating losses since inception. As at February 28, 2022, the Company has a working capital deficit of ~~Operation~~$891,146 and has reported an accumulated deficit of $4,157,899. The Company requires additional funding to meet its ongoing obligations and to fund anticipated operating losses. The ability of the Company to continue as a going concern is dependent on raising capital to fund its initial business plan and ultimately to attain profitable operations. Accordingly, these factors raise substantial doubt as to the Company’s ability to continue as a going concern for a period of 12 months from the issue date of these financials. The Company intends to continue to fund its business by way of private placements and advances from related parties as may be required. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

~~The following discussion should be read in conjunction with the~~NOTE ~~financial~~3 ~~statements~~– ~~and~~RELATED ~~related~~PARTY notes which are included elsewhere in this prospectus. Statements made below which are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties including, but not limited to, general economic conditions and our ability to market our product.TRANSACTIONS

~~The~~For the ~~business~~periods ~~objective~~presented ofin ~~GLOBAL~~balance ~~was~~sheet, tothe ~~position~~Company ~~AquaBoost™~~owes $12, ~~our~~500 ~~initial~~to ~~product~~CEO ~~being~~for ~~offered,~~management asfees afor ~~top~~period ~~quality~~ended ~~oxygenated~~February ~~water~~28,2022. in For the ~~specialty~~period ~~waters~~ended ~~market.~~February ~~Our~~28, ~~oxygenation~~2021, ~~level~~the ~~(up to~~Company ~~100~~owes ~~ppm~~CEO, ~~and~~Leonard ~~greater)~~Stella $12,500 for ~~the~~management ~~ability~~fees. ofThe ~~our~~total ~~bottled~~amount ~~water~~owing to the ~~retain~~Company’s ~~this~~current ~~level~~CEO as of ~~oxygenation~~February 28, ~~even~~2022 ~~over~~was ~~lengthy periods of time~~ $850,484 and ~~the~~$837,984 ~~purity~~as of ~~our~~November ~~product~~30, ~~we believed~~2021, ~~should~~respectively. ~~have~~The balances ~~given~~due usare ~~the~~unsecured ~~ability~~and tonon-interest-bearing ~~become~~with ano ~~staple~~set interms ~~this~~of ~~specialty waters niche~~repayment.

~~We set a conservative sales objective for our product, but no assurances can be given~~NOTE ~~that~~4 ~~the~~– Company will meet their goals. The Company will also attempt to engage in partnering with other beverage distributors or leasing its technology for royalties in those regions and for those products where it will not negatively impact on potential AquaBoost™ sales.EQUITY

~~GLOBAL BIOTECH CORP. ("GLOBAL"), formerly (SWORD COMP-SOFT CORP.) was~~The ~~organized~~Company ~~on November 2~~has 80, ~~1998. Its goal was to bring interactive healthcare information services utilizing the Internet to the consumer~~000,000 preferred ~~the~~shares ~~end~~authorized ~~user, to access what they, as individuals, need. As of March 5, 2003 this business was sold along~~ with ~~the~~ ~~assumption of~~ a ~~note~~par ~~payable~~value ~~in the amount~~ of $~~700,000 to Millenia Hope Inc~~0.,0001 ~~its~~that ~~former~~are ~~parent~~non-voting ~~corporation.~~in Interms ~~exchange, GLOBAL received 30.7 million shares~~ of ~~its outstanding common shares held by Millenia Hope Inc. Subsequently, GLOBAL acquired the exclusive 10 year North American licensing~~ rights ~~to a vehicle tracking system in exchange for 30~~.7 ~~million of its common~~The ~~shares.~~Company ~~As of February 24~~has 260, ~~2005~~000,000 common ~~GLOBAL’s~~shares ~~Board~~authorized ~~of Directors concluded that its attempt to enter the vehicle tracking business was unsuccessful and entered into an agreement~~ with ~~Advanced~~a ~~Fluid~~par ~~Technologies~~value ~~Inc~~of $0.,0001 per ~~on August 15, 2007, to acquire its assets pursuant to entering the oxygenated bottled water, market~~share.

~~GLOBAL’s~~There are ~~goal~~244,038,890 iscommon toshares ~~position~~issued ~~AquaBoost(TM),~~and ~~the~~outstanding ~~bottled~~as ~~oxygenated water~~of ~~product~~February ~~it acquired~~28, as2022 anwhich ~~energizing~~are ~~alternative~~voting toin ~~soft~~terms ~~drinks~~of rights and as aof ~~beverage~~February ~~with more health benefits than ordinary~~28, ~~water~~2021 respectively. ToCommon ~~date,~~shares ~~the~~have ~~aforementioned~~been ~~product~~issued ~~has had minimal sales~~ and ~~the~~paid ~~Company~~in ~~will~~amount ~~endeavor,~~of ~~but can offer no guarantees~~$24,403 ~~to raise~~par ~~its~~value ~~sales~~since ~~level significantly~~inception.

As of September 10, 2013, Global acquired from Purthanol International all the intellectual property, process know-how and methodology, etc. for the production of Athanol, a green- technology ethanol fuel alternative, produced via the Purthanol Process. Further, the Company has acquired purchase orders of $28.5 million USD for the purchase of ethanol or Athanol from Purthanol International, delivery within the ensuing 12 months. Any other revenue generated via the Purthanol Process, will belong wholly and solely to Global as of the signing of this Agreement. The consideration for the above was 70 million (70,000,000) restricted common shares, valued at $0.01 per share or $700,000 USD.8

~~On September 16, 2013 the Company sold its first license to the rights to utilize~~Item ~~the~~2. ~~Purthanol~~Management’s ~~process~~Discussion ~~for~~and ~~the~~Analysis ~~production~~ of ~~Athanol~~Financial ~~for~~Condition ~~the~~and ~~Province~~Results of ~~Quebec, Canada~~Operations. ~~Mr. Yvon Brin purchased the license on behalf of a newly formed corporation, Purthanol Quebec, that now owns this license.~~

~~GLOBAL’s~~This section ~~registration~~of ~~statement,~~this Form 10-Q includes a number of forward-looking statements that reflect our current views with ~~the~~respect ~~Security~~to future events and ~~Exchange~~financial ~~Commission,~~performance. ~~was accepted~~Forward-looking onstatements ~~July~~are 16often identified by words like believe, ~~2001~~expect, estimate, anticipate, intend, project and itsimilar ~~was~~expressions, ~~cleared~~or bywords ~~FINRA~~which, onby ~~June~~their 16nature, ~~2009~~refer to ~~trade~~future ~~its~~events. ~~shares~~You should not place undue certainty on ~~the~~these forward-looking ~~OTC:~~statements. BBThese forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

~~On July 3, 2013 Mr. Leonard~~Results ~~Stella~~of ~~joined the Company as its CEO and a Director.~~Operations

OnFor the ~~July~~three-month 3periods ended February 28, ~~2013~~2022 Mrand 2021, we had no revenue. ~~Yehuda~~Operating expenses for the three-month period ended February ~~Kops~~28, ~~joined~~2022 totaled $13,913 resulting in a net loss of $13,913. The net loss for the ~~Company~~three-month asperiod ~~its~~ended ~~CFO~~February 28, 2022 is a result of administrative fees of $12,500 and professional fees comprised of SEC filing fees of $906;. Expenses for the comparative three-month period ended February 28, 2021 is a ~~Director~~result of administrative fees, and brokerage fees totaling $13,007 resulting in a net loss of $13,007. The increase in expenses between February 28, 2022 and 2021 was primarily due to an increase in SEC filing fees, between the two comparative periods.

~~On September 3, 2013 Mr. Louis~~Capital ~~Greco~~Resources ~~resigned~~ and ~~Mr. Louis Pharand took his position in the Company as its President and a Director.~~Liquidity

OnNo substantial ~~September~~revenues 3,are ~~2013~~anticipated Mruntil we have implemented our plan of operations. ~~Serge~~With ~~Mersilian~~the ~~joined~~exception of cash advances from our sole Chief Executive Officer, we have no other source for funding the Company at this time. We must raise cash to implement our strategy and stay in business. If we are unable to raise additional funds, there is substantial doubt as ~~its~~to ~~Director~~our ofability ~~Communications~~to continue as a going concern.

~~Three~~As of ~~months~~February ~~ended~~28, ~~August 31~~2022, ~~2013~~we had $nil in assets as compared to ~~August~~$nil 31in assets at November 30, ~~2012~~2021. The funds available to the Company will not be sufficient to fund the planned operations of the Company and maintain operations. As of February 28, 2022, the Company’s sole officer and director, Mr. Leonard Stella, is owed by the Company $850,484. Mr. Stella has indicated he is willing to make additional financial commitments if required to maintain the operating status of the Company, in the form of a non-secured loan for the next twelve months if no other funds are obtained by the Company, but the total amount that they are willing to invest has not yet been determined and there is no contract or written agreement in place.

~~Marketing costs were $30,273 in 2013 and $0 in 2012, as we~~Off-balance ~~are~~sheet embarking in getting our latest product, Athanol, into as many relationships and markets as possible. Professional, selling, general and administrative in 2013 was $48,854 and $15,336 in 2012, a difference of $33,518. This was primarily due to an additional $23,080 of consulting fees, again as we position our product and reorient the Company. Also we had $4,961 in additional regulatory fees, primarily bringing the franchise taxes to date, and higher office and other SG&A expenses.arrangements

WeThe company ~~had~~has ~~net~~no ~~interest~~off-balance ~~expense,~~sheet arrangements that have or are reasonably likely to have a current or future effect or change on ~~our~~the Company’s ~~loans~~financial condition, revenues or expenses, results of ~~$14~~operations,~~387~~ inliquidity, ~~2013~~capital expenditures or capital resources ~~and~~that ~~$14,962~~are inmaterial ~~2012~~to ~~and~~investors. ~~$15~~The term “off-balance sheet arrangement” generally means any transaction,~~878~~ ofagreement ~~foreign~~or ~~exchange~~other contractual ~~losses~~arrangement into ~~2012~~which ~~vs.~~an entity unconsolidated with the Company is a ~~gain~~party, ofunder ~~$11~~which the Company has (i) any obligation arising under a guarantee contract,~~269~~ derivative instrument or variable interest; or (ii) a retained or contingent interest in ~~2013~~assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

AsItem 3. aQuantitative ~~result~~and ofQualitative ~~the~~Disclosures ~~above,~~About weMarket ~~had a net loss of $82,245 in 2013 and $46,176 in 2012~~Risk.

~~Nine~~We are ~~months~~a ~~ended~~smaller ~~August~~reporting ~~31,~~company ~~2013~~as ~~compared~~defined by Rule 12b-2 of the Exchange Act and are not required to ~~August~~provide ~~31,~~the ~~2012~~information required under this item.

~~Marketing costs were $30,273 in 2013 and $0 in 2012, as we are embarking in getting~~Item ~~our latest product, Athanol, into as many relationships and markets as possible~~4. ~~Professional,~~Controls ~~selling, general~~ and ~~administrative in 2013 was $185,552 and $45,978 in 2012, a difference of $139,574~~Procedures. This was primarily due to an additional $100,000 in administrative fees and $6,000 of auto expenses, as agreed to by a Resolution of the Board vs. none in 2012. Also, an additional $23,080 of consulting fees, again as we position our product and reorient the Company. Also we had $4,961 in additional regulatory fees, primarily bringing the franchise taxes to date, and higher office and other SG&A expenses.

~~We had net interest expense, on our loans, of $44,577 in 2013~~Disclosure ~~and~~Controls ~~$44,150 in 2012~~ and ~~$15,878 of foreign exchange losses in 2012 vs. a gain of$30,531 in 2013.~~Procedures

AsDisclosure controls aand ~~result~~procedures ofare controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the ~~above~~Securities Exchange Act of 1934 is recorded, weprocessed, ~~had~~summarized aand ~~net~~reported, ~~loss~~within ofthe ~~$229~~time period specified in the SEC's rules and forms. Disclosure controls and procedures include,~~871~~ without limitation, controls and procedures designed to ensure that information required to be disclosed in ~~2013~~our reports filed or submitted under the Securities Exchange Act of 1934 is accumulated and~~$106~~ communicated to management including our principal executive officer and principal financial officer as appropriate,~~006~~ to inallow ~~2012~~timely decisions regarding required disclosure.

~~Liquidity and cash flow needs of the company~~9

~~From~~In connection ~~June~~with 1this quarterly report, ~~2013~~as torequired ~~August~~by ~~31,~~Rule ~~2013~~15d-15 under the ~~company~~Securities ~~used~~Exchange ~~$133~~Act of 1934,~~684~~ we have carried out an evaluation ~~from~~of ~~operating~~the ~~activities~~effectiveness ~~while~~of ~~recording~~the nodesign ~~revenues~~and operation of our company’s disclosure controls and procedures. ~~From~~This ~~September~~evaluation 1,was ~~2013~~carried out tounder ~~November~~the ~~30,~~supervision ~~2013,~~and with the ~~fiscal~~participation ~~year-~~of ~~end~~our company’s management, ~~the~~including our company’s principal executive ~~net~~officer ~~cash~~and ~~flow~~principal ~~needs~~financial ~~will~~officer. beBased ~~$280~~upon that evaluation,~~000~~ our company’s principal executive officer and principal financial officer concluded that subject to the inherent limitations noted in this Part II, Item 9A(T) as of February 28, 2022, our disclosure controls and procedures were not effective due to the existence of material weaknesses in our internal controls over financial reporting.

~~Item~~Changes in ~~4T.~~Internal ~~CONTROLS~~Control ~~AND~~Over ~~PROCEDURES~~Financial ~~QUARTERLY EVALUATION OF THE COMPANY’S DISCLOSURE CONTROLS AND INTERNAL CONTROLS.~~Reporting

AsThere were ofno ~~October~~changes 1,in ~~2013, the date of the report,~~ our ~~Principal~~internal ~~Executive~~control ~~Officer,~~over ~~(CEO)~~financial ~~and~~reporting ~~Chief Financial Officer~~ (~~CFO) evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures~~ as defined in Rule 13a-15(f) or 15d-15(ef)) ~~under~~during the ~~Securities~~quarter ~~Exchange~~ended February ~~act of 1934~~28, as ~~amended.~~2022 ~~Based~~that ~~upon~~have ~~that~~materially ~~evaluation~~affected, ~~the~~or ~~Principal~~are ~~Executive~~reasonably ~~and~~likely ~~Financial~~to ~~Officer~~materially ~~concluded that~~affect, asour ofinternal ~~August 31, 2013, the Company’s disclosure~~ controls ~~and~~over ~~procedures are effective~~financial reporting.

~~Further, there was no change during the last~~PART ~~quarter~~II—OTHER ~~in the Company’s internal control over financial reporting that has materially affected or is likely to materially affect, the Company’s internal control over financial reporting.~~INFORMATION

~~Part~~Item 1. IILegal ~~other information~~Proceedings.

~~Item~~Currently we 2:are ~~Sales~~not ofinvolved ~~Unregistered~~in ~~securities~~any pending litigation or legal proceeding.

Item 1A. Risk Factors.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 2. Unregistered Sales of Securities and Use of Proceeds.

None

Item 3. ~~(6)~~Defaults ~~Reports~~Upon onSenior ~~Form 8-K~~Securities.

~~Changes in Principal Officers and Directors~~None

Item 4. Mine Safety Disclosures.

N/A

Item 5. Other Information.

Item 6. Exhibits.

EXHIBIT INDEX

3.1

Certificate of Incorporation as previously filed with the SEC on Form 10-12G/A May 3, 2022

3.2

Bylaws of Purthanol Resources Ltd. – formerly known as Sword Comp-Soft Corp as previously filed with the SEC ```````````on`Form SB2 on January 18, 2001 ```````````https://www.sec.gov/Archives/edgar/data/1126162/000089155401500243/d24433_ex3-2.txt

31.1

Certification of Chief Executive Officer pursuant to Rule 13(a)-14(a)/15(d)-14(a) of the Securities Act of 1934

31.2

Certification of Chief Financial Officer pursuant to Rule 13(a)-14(a)/15(d)-14(a) of the Securities Act of 1934 *

32.1

Certification of Chief Executive Officer Executive Officer under Section 1350 as Adopted pursuant Section 906 of the Sarbanes-Oxley Act of 2002

32.2

Certification of Chief Financial Officer under Section 1350 as Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**

* Included in Exhibit 31.1

** Included in Exhibit 32.1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~Registrant~~registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: October 3, 2013	By: /s/ Leonard Stella
	Purthnol Resources Ltd.
	Leonard Stella , CEO
	(Registrant)
	Principal Executive Officer
Date: November 4, 2022	By: /s/ Leonard Stella
	Leonard Stella
	President and Director
	Principal and Executive Officer
	Principal Financial Officer
	Principal Accounting Officer

Filing Compare · Purthanol Resources Ltd